Glucagon-Like Peptide-1 (GLP-1) during Ramadan: Narrative Review of the Published Literature.

IF 3.8 Q2 ENDOCRINOLOGY & METABOLISM Journal of Obesity Pub Date : 2023-12-26 eCollection Date: 2023-01-01 DOI:10.1155/2023/8626081
Khalid Mohammed Alayed
{"title":"Glucagon-Like Peptide-1 (GLP-1) during Ramadan: Narrative Review of the Published Literature.","authors":"Khalid Mohammed Alayed","doi":"10.1155/2023/8626081","DOIUrl":null,"url":null,"abstract":"<p><p>Ramadan fasting, a religious practice observed by Muslims worldwide, involves abstaining from eating, drinking, smoking, and using oral medications from dawn to dusk during the ninth lunar month. Studies have demonstrated that fasting during Ramadan has been shown to increase HDL cholesterol, leptin, adiponectin, and insulin sensitivity, as well as lower several hemostatic risk factors for cardiovascular diseases. Additionally, it may result in a drop in blood sugar levels, especially in diabetics who are also on blood sugar-lowering medicine. Hypoglycemia, characterized by low blood sugar levels, could also result from fasting during Ramadan. The GLP-1 (glucagon-like peptide-1) hormone plays a significant role in regulating glucose metabolism and insulin secretion, and Ramadan fasting can affect its production and release in the gut. Research contributes to our understanding of the utilization of GL-1 medications during Ramadan among patients, broadening therapy alternatives and offering insightful information for well-informed decision-making. Therefore, this narrative review aims to explore the current evidence that studies the safety and efficacy of GLP-1 agonists during Ramadan for nondiabetic and diabetic patients to ensure healthy fasting during Ramadan.</p>","PeriodicalId":16628,"journal":{"name":"Journal of Obesity","volume":"2023 ","pages":"8626081"},"PeriodicalIF":3.8000,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10761230/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Obesity","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2023/8626081","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Ramadan fasting, a religious practice observed by Muslims worldwide, involves abstaining from eating, drinking, smoking, and using oral medications from dawn to dusk during the ninth lunar month. Studies have demonstrated that fasting during Ramadan has been shown to increase HDL cholesterol, leptin, adiponectin, and insulin sensitivity, as well as lower several hemostatic risk factors for cardiovascular diseases. Additionally, it may result in a drop in blood sugar levels, especially in diabetics who are also on blood sugar-lowering medicine. Hypoglycemia, characterized by low blood sugar levels, could also result from fasting during Ramadan. The GLP-1 (glucagon-like peptide-1) hormone plays a significant role in regulating glucose metabolism and insulin secretion, and Ramadan fasting can affect its production and release in the gut. Research contributes to our understanding of the utilization of GL-1 medications during Ramadan among patients, broadening therapy alternatives and offering insightful information for well-informed decision-making. Therefore, this narrative review aims to explore the current evidence that studies the safety and efficacy of GLP-1 agonists during Ramadan for nondiabetic and diabetic patients to ensure healthy fasting during Ramadan.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
斋月期间的胰高血糖素样肽-1 (GLP-1):已发表文献的叙述性回顾。
斋月斋戒是全世界穆斯林信奉的一种宗教习俗,即在农历九月从黎明到黄昏期间禁食、禁饮、禁烟和禁用口服药物。研究表明,在斋月期间禁食可增加高密度脂蛋白胆固醇、瘦素、脂肪连通素和胰岛素敏感性,并降低心血管疾病的几种止血风险因素。此外,它还可能导致血糖水平下降,尤其是对于同时服用降血糖药物的糖尿病患者。斋月期间的禁食也可能导致低血糖症,即低血糖。GLP-1(胰高血糖素样肽-1)激素在调节葡萄糖代谢和胰岛素分泌方面发挥着重要作用,而斋月禁食会影响其在肠道中的产生和释放。相关研究有助于我们了解患者在斋月期间对 GL-1 药物的使用情况,从而拓宽治疗选择范围,并为做出明智决策提供有见地的信息。因此,本综述旨在探讨目前研究斋月期间 GLP-1 激动剂对非糖尿病患者和糖尿病患者的安全性和有效性的证据,以确保斋月期间的健康禁食。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Obesity
Journal of Obesity ENDOCRINOLOGY & METABOLISM-
CiteScore
7.50
自引率
3.00%
发文量
19
审稿时长
21 weeks
期刊介绍: Journal of Obesity is a peer-reviewed, Open Access journal that provides a multidisciplinary forum for basic and clinical research as well as applied studies in the areas of adipocyte biology & physiology, lipid metabolism, metabolic syndrome, diabetes, paediatric obesity, genetics, behavioural epidemiology, nutrition & eating disorders, exercise & human physiology, weight control and health risks associated with obesity.
期刊最新文献
Association between Socioeconomic Position of the Family and Adolescent Obesity in Germany-Analysis of the Mediating Role of Familial Determinants. Body Mass Index and Prevalence of Obesity in Brazilian Adult Women: Temporal Comparison of Repeated Population-Based Cross-Sectional Surveys. Overweight and Obesity Among In-School Children and Adolescents (5-19 Years) in Ghana: A Scoping Review of Prevalence and Risk Factors. Genetic Variations in AMPK, FOXO3A, and POMC Increase the Risk of Extreme Obesity. Microarray Analysis of Visceral Adipose Tissue in Obese Women Reveals Common Crossroads Among Inflammation, Metabolism, Addictive Behaviors, and Cancer: AKT3 and MAPK1 Cross Point in Obesity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1